Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001140361-17-041187)

Filing Details

Accession Number:: 0001140361-17-041187
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-11-06 21:27:55
Reporting Period:: 2017-11-02

Accepted Time:: 2017-11-06 21:27:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1061027	Sunesis Pharmaceuticals Inc	SNSS	Pharmaceutical Preparations (2834)	943295878

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1687078	Mpm Oncology Impact Management Lp	450 Kendall Street Cambridge MA 02142		No	No	Yes	No
1691428	L.p. Fund Impact Oncology Ubs	450 Kendall Street Cambridge MA 02142		No	No	Yes	No
1721035	Mpm Oncology Impact Management Gp Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142		No	No	Yes	No
1721036	L.p. Management (Cayman) Fund Impact Oncology	450 Kendall Street Cambridge MA 02142		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-11-02	25,300	$2.59	3,275,300	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-03	40,000	$2.89	3,315,300	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-06	16,200	$2.77	3,331,500	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Footnotes

MPM Oncology Impact Management GP LLC ("MPM GP") is the general partner of MPM Oncology Impact Management LP ("MPM Management"), which is the general partner of Oncology Impact Fund (Cayman) Management L.P. ("MPM Cayman"), which is the general partner of UBS Oncology Impact Fund L.P. ("UBS Oncology"). The reported securities are owned indirectly by MPM GP, MPM Management and MPM Cayman, and are owned directly by UBS Oncology.